BKYI — BIO-key International Income Statement
0.000.00%
- $4.62m
- $4.52m
- $6.93m
- 33
- 56
- 79
- 57
Annual income statement for BIO-key International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | PRESS |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.84 | 5.11 | 7.02 | 7.75 | 6.93 |
Cost of Revenue | |||||
Gross Profit | 2.04 | 3.44 | 4.58 | 1.43 | 5.64 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.54 | 10.1 | 17.4 | 16.6 | 10.9 |
Operating Profit | -5.7 | -4.94 | -10.4 | -8.83 | -4.01 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.67 | -5.07 | -11.9 | -8.66 | -4.32 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.67 | -5.07 | -11.9 | -8.52 | -4.32 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.67 | -5.07 | -11.9 | -8.52 | -4.32 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.79 | -5.07 | -11.9 | -8.52 | -4.32 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -35.6 | -11.7 | -23 | -15.2 | -2.1 |